INtRON Biotechnology Total Debt vs. Shares Owned By Institutions
| 048530 Stock | KRW 5,440 110.00 1.98% |
For INtRON Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of INtRON Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well iNtRON Biotechnology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between INtRON Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of iNtRON Biotechnology over time as well as its relative position and ranking within its peers.
INtRON |
iNtRON Biotechnology Shares Owned By Institutions vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining INtRON Biotechnology's current stock value. Our valuation model uses many indicators to compare INtRON Biotechnology value to that of its competitors to determine the firm's financial worth. iNtRON Biotechnology is the top company in total debt category among its peers. It also is number one stock in shares owned by institutions category among its peers . The ratio of Total Debt to Shares Owned By Institutions for iNtRON Biotechnology is about 1,991,161,074 . Comparative valuation analysis is a catch-all model that can be used if you cannot value INtRON Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for INtRON Biotechnology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.INtRON Total Debt vs. Competition
iNtRON Biotechnology is the top company in total debt category among its peers. Total debt of Health Care industry is presently estimated at about 60.73 Billion. INtRON Biotechnology totals roughly 16.13 Billion in total debt claiming about 27% of equities under Health Care industry.
INtRON Shares Owned By Institutions vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
INtRON Biotechnology |
| = | 16.13 B |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
INtRON Biotechnology |
| = | 8.10 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
INtRON Shares Owned By Institutions Comparison
INtRON Biotechnology is currently under evaluation in shares owned by institutions category among its peers.
INtRON Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in INtRON Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, INtRON Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of INtRON Biotechnology's change in net profit over the period of time. It can combine multiple indicators of INtRON Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
iNtRON Biotechnology, Inc., a biotechnology company, develops bacterial bio-drugs for the treatment of infectious diseases. In addition, the company develops drugs targeting functional moieties, including axakacin, pterostilbene, methylated flavonoid, etc. for use in silver and brain industries. iNtRON Biotechnology, Inc. was founded in 1999 and is headquartered in Seongnam, South Korea. iNtRON Bio is traded on Korean Securities Dealers Automated Quotations in South Korea.
INtRON Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on INtRON Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of INtRON Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the INtRON Biotechnology's important profitability drivers and their relationship over time.
Use INtRON Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if INtRON Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in INtRON Biotechnology will appreciate offsetting losses from the drop in the long position's value.INtRON Biotechnology Pair Trading
iNtRON Biotechnology Pair Trading Analysis
The ability to find closely correlated positions to INtRON Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace INtRON Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back INtRON Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling iNtRON Biotechnology to buy it.
The correlation of INtRON Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as INtRON Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if iNtRON Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for INtRON Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your INtRON Biotechnology position
In addition to having INtRON Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run High Dividend Yield ETFs Thematic Idea Now
High Dividend Yield ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Dividend Yield ETFs theme has 107 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Dividend Yield ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in INtRON Stock
To fully project INtRON Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of iNtRON Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include INtRON Biotechnology's income statement, its balance sheet, and the statement of cash flows.